Genentech's Trastuzumab Emtansine (T-...

Genentech's Trastuzumab Emtansine (T-DM1) Reduces The Risk Of Cancer Worsening

There are 1 comment on the MediLexicon story from Jun 4, 2012, titled Genentech's Trastuzumab Emtansine (T-DM1) Reduces The Risk Of Cancer Worsening. In it, MediLexicon reports that:

Roche announced today that it's division, known as Genentech, has produced positive results in a phase three EMILIA study of a drug called trastuzumab emtansine .

Join the discussion below, or Read more at MediLexicon.

Since: Dec 05

Reading, PA

#1 Jun 19, 2012
The EMILIA study found that trastuzumab emtansine (T-DM1) can improve progression-free survival in "some" women with metastatic breast cancer. The final arbiter of clinical approval is overall survival. Median overall survival for patients treated with T-DM1 was not reached. Drug response is not a reliable predictor of overall survival. Median progression-free survival was longer in patients treated with T-DM1 than in those treated with the standard therapy (9.6 vs 6.4 months). The difference reached is statistically significant?

The so-called immunoconjugates or antibody-drug conjugates (ADCs) are unique therapeutics that have become the focus of a plethora of recent and ongoing clinical trials, and for the first time since 2000 when Mylotarg (gemtuzumab ozogamicin) was approved in AML, the FDA gave the green light for another ADC, namely Adcetris (brentuximab vedotin) for the management of Hodgkins Lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL), like its sister agent in HER2-positive breast cancer, T-DM1, and other ADCs.

The ADCs do not work for all patients, T-DM1 is meant to treat only roughly 20 percent of breast cancer cases characterized by an abundance of that protein, and they are not totally free of side effects. And of course, T-DM1 is also likely to be very expensive, costing more than $100,000 for a typical course of treatment. One note: Mylotarg was removed from the market in 2010 after newer studies showed it did not prolong lives and had safety problems. At initial approval, Mylotarg was associated with a serious liver condition called veno-occlusive disease, which can be fatal.

T-DM1 is a "large molecule" and does not cross the blood-brain barrier (BBB). Some think that those on the T-DM1, they should also give the ladies some straight Herceptin, and give a certain amount of protection. The only way for that to happen is a patient may also have to be subjected to an "intrathecal" injection of T-DM1. Herceptin does not cross the BBB because it is a "large molecule" drug. Some on the trial developed brain metastases. Patients on T-DM1 will have to be on it "indefinitely" or until progression. Some on the trial developed brain metastases.

One thing you can definitely say is that T-DM1 is an investigational agent, or just plain experimental.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Genentech Discussions

Title Updated Last By Comments
What gives (Feb '15) Feb '15 Bookrep 1
News Company seeks approval for skin cancer drug (Jan '15) Jan '15 Cathy Smith 1
News UCSF geneticist joins Google's Calico project (Apr '14) Apr '14 Guest 1
Zelboraf Ripoff of Melanoma Patients (Nov '11) Nov '13 Ye li 4
News Tarceva meets goal in first-line lung cancer trial (Nov '08) Nov '13 Avi 5
News Studies: Avastin may fight early breast cancers (Mar '12) Sep '13 Sabastian 2
News Questions Swirl Around Avastin (Jun '09) Sep '13 Jesus 2
More from around the web